Session Type
Meeting
Search Results for Coagulation
Abstract Number: 75
Hospital Medicine 2020, Virtual Competition
Background: Atrial fibrillation (AF) is strongly age-dependent, and with a growing geriatric population, the incidence and prevalence of AF is expected to increase in the United States. As a result, the number of patients at risk of a thromboembolic event due to AF is also expected to increase. Although bleeding associated with mechanical falls is […]
Abstract Number: 83
Hospital Medicine 2018; April 8-11; Orlando, Fla.
Background: Aging is associated with increased prevalence of atrial fibrillation and thrombophlebitis. Anticoagulation has been shown to be effective in preventing thromboembolic events in AF patients and treatment of thrombophlebitis. Non-vitamin k antagonist oral anticoagulants (NOACs) have been shown to be non-inferior or even superior to warfarin for long-term stroke prevention and thrombophlebitis treatment. In […]
Abstract Number: 90
SHM Converge 2021
Background: Patients with COVID-19 have increased rates of venous thromboembolism, however, there is currently no standardized approach to anticoagulation (AC) therapy particularly with respect to the proper dose of anticoagulation (prophylactic or therapeutic). Many observational studies have shown a mortality benefit in using prophylactic AC for hospitalized patients with COVID-19. A few studies have reported […]
Abstract Number: B9
SHM Converge 2022
Background: Patients with end stage renal disease (ESRD) are at significantly increased risk for both thrombosis and bleeding relative to those with normal renal function, which makes anticoagulation particularly challenging. Evidence suggests that rivaroxaban and dabigatran are associated with a higher risk of bleeding in ESRD patients. To date, no large national cohort studies have […]
Abstract Number: 105
Hospital Medicine 2020, Virtual Competition
Background: Transjugular intrahepatic portosystemic shunt (TIPS) creation is a commonly utilized procedure used for patients with chronic liver disease and resistant portal hypertension. Previous studies have explored the trends and short-term outcomes in TIPS procedures. This study aims to further compare short-term in-hospital outcomes of patients with coagulation disorders when undergoing TIPS. Methods: This retrospective […]
Abstract Number: 116
Hospital Medicine 2018; April 8-11; Orlando, Fla.
Background: Vitamin K antagonists (VKA) remain widely used in the treatment of venous thromboembolism (VTE). During surgical interventions, the prevention of recurrent VTE must be weighed against the increased bleeding risk conferred by anticoagulation. There is a lack of strong evidence to guide the optimal periprocedural management of anticoagulation in patients with prior VTE, and […]
Abstract Number: 128
Hospital Medicine 2020, Virtual Competition
Background: For patients with atrial fibrillation (AF) who undergo percutaneous coronary intervention (PCI), antithrombotic therapy including oral anticoagulants (OAC) and antiplatelets are indicated. The optimal combination is not known. We investigated the efficacy and safety of different antithrombotic strategies in patients with AF undergoing PCI. Methods: PUBMED and EMBASE were searched through September 2019 for […]
Abstract Number: 129
Hospital Medicine 2020, Virtual Competition
Background: Cancer-associated thrombosis (CAT) is a common complication in patients with malignancy. Management of venous thromboembolism (VTE), in these patients, is challenging due to the high risk of recurrence and inherent risk of bleeding in this population. Direct oral anticoagulants (DOACs) have emerged as a treatment options for CAT. As yet there have not been […]
Abstract Number: 143
Hospital Medicine 2018; April 8-11; Orlando, Fla.
Background: Warfarin and other anticoagulants increase the risk of hemorrhagic complications, including upper gastrointestinal hemorrhages (UGIB). Warfarin is commonly used in the management of atrial fibrillation to reduce the risk of ischemic stroke, and frequently resumed following UGIB. However, optimal timing of reinitiation remains unclear. Theory suggests that resuming warfarin immediately after UGIB would lead […]
Abstract Number: 157
Hospital Medicine 2018; April 8-11; Orlando, Fla.
Background: Warfarin-associated adverse drug events are dangerous, common, and costly. Anticoagulation safety is a national priority. While multiple tools exist for warfarin management in the outpatient setting, there is a dearth of guidance with regard to inpatient management. This study aims to: 1) describe a health system’s inpatient chronic warfarin quality metrics, defined by International […]